Solventum faces Trian call to simplify business and change leadership

7 articles · Updated · MarketWatch · Apr 30

In an open letter, Trian, which owns nearly 5% of the healthcare-products company, said patience had run out after weak performance since Solventum's 2024 spinoff from 3M.
The activist investor urged divesting noncore units including health-information systems, cutting costs and prioritising share buybacks, while criticising executive pay and saying other large shareholders are frustrated.
Trian also said Solventum's board rejected proposals to add one Trian employee and an independent Fortune 100 representative, as the company continues to trade below expectations set at the spinoff.

With Trian pushing for change and Solventum already restructuring, who will ultimately determine the company's future—activists or management?

Is Solventum's Health Information Systems segment a hidden strength or a distraction, given activist calls for divestiture despite its growth?

Will the surge in healthcare activism deliver real value for shareholders, or just fuel more boardroom battles and uncertainty?